Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
NCT00062439 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining cisplatin and etoposide with radiation therapy may shrink the tumor so it can be removed by surgery. Giving docetaxel after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well giving chemoradiotherapy together with cisplatin and etoposide followed by surgery and docetaxel works in treating patients with newly diagnosed Pancoast tumors, a type of non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG docetaxel
- DRUG etoposide
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute — Chanute
- Cancer Center of Kansas, PA - Dodge City — Dodge City
- Cancer Center of Kansas, PA - El Dorado — El Dorado
- Cancer Center of Kansas, PA - Kingman — Kingman
- Southwest Medical Center — Liberal
- Cancer Center of Kansas, PA - Newton — Newton
- Cancer Center of Kansas, PA - Parsons — Parsons
- Cancer Center of Kansas, PA - Pratt — Pratt
- Cancer Center of Kansas, PA - Salina — Salina
Illinois
- Rush-Copley Cancer Care Center — Aurora
- Joliet Oncology-Hematology Associates, Limited - West — Joliet
- Cardinal Bernardin Cancer Center at Loyola University Medical Center — Maywood
- Regional Cancer Center at Memorial Medical Center — Springfield
- Carle Cancer Center at Carle Foundation Hospital — Urbana
- CCOP - Carle Cancer Center — Urbana
Alabama
- Mobile Infirmary Medical Center — Mobile
Colorado
- Poudre Valley Hospital — Fort Collins
Florida
- Mayo Clinic - Jacksonville — Jacksonville
Indiana
- Saint Anthony Memorial Health Centers — Michigan City
Iowa
- Holden Comprehensive Cancer Center at University of Iowa — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2003-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062439
The ClinicalTrials.gov registry entry for NCT00062439 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 5 interventions — of which cisplatin is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00062439 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Kansas, Illinois, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00062439 about?
NCT00062439 is a clinical study titled "S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors". RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining cisplatin and etoposide with radiation therapy may shrink t...
What is the current status of trial NCT00062439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2003-07. Estimated completion is 2010-12.
What conditions does trial NCT00062439 study?
This clinical trial studies the following conditions: Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00062439?
The interventions under investigation include: cisplatin (DRUG), docetaxel (DRUG), etoposide (DRUG), conventional surgery (PROCEDURE), radiation therapy (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00062439?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00062439 being conducted?
This trial has 20 study locations across Alabama, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.